AR035890A1 - Derivados de dipeptido con actividad inhibitoria de las enzimas convertidoras de angiotensina, de endotelina y de la enzima endopeptidasa neutra - Google Patents

Derivados de dipeptido con actividad inhibitoria de las enzimas convertidoras de angiotensina, de endotelina y de la enzima endopeptidasa neutra

Info

Publication number
AR035890A1
AR035890A1 ARP020101736A ARP020101736A AR035890A1 AR 035890 A1 AR035890 A1 AR 035890A1 AR P020101736 A ARP020101736 A AR P020101736A AR P020101736 A ARP020101736 A AR P020101736A AR 035890 A1 AR035890 A1 AR 035890A1
Authority
AR
Argentina
Prior art keywords
lower alkyl
carbocyclic
heterocyclic aryl
biaryl
cycloalkyl
Prior art date
Application number
ARP020101736A
Other languages
English (en)
Spanish (es)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of AR035890A1 publication Critical patent/AR035890A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
ARP020101736A 2001-05-15 2002-05-13 Derivados de dipeptido con actividad inhibitoria de las enzimas convertidoras de angiotensina, de endotelina y de la enzima endopeptidasa neutra AR035890A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29108801P 2001-05-15 2001-05-15
US33957501P 2001-12-11 2001-12-11

Publications (1)

Publication Number Publication Date
AR035890A1 true AR035890A1 (es) 2004-07-21

Family

ID=26966569

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP020101736A AR035890A1 (es) 2001-05-15 2002-05-13 Derivados de dipeptido con actividad inhibitoria de las enzimas convertidoras de angiotensina, de endotelina y de la enzima endopeptidasa neutra

Country Status (23)

Country Link
US (3) US6777443B2 (enExample)
EP (2) EP1392720A2 (enExample)
JP (1) JP4390458B2 (enExample)
KR (1) KR100908152B1 (enExample)
CN (1) CN1649893A (enExample)
AR (1) AR035890A1 (enExample)
AU (1) AU2002314067B2 (enExample)
BR (1) BR0209652A (enExample)
CA (1) CA2449292A1 (enExample)
CO (1) CO5540347A2 (enExample)
CZ (1) CZ20033077A3 (enExample)
HU (1) HUP0304084A3 (enExample)
IL (1) IL158772A0 (enExample)
MX (1) MXPA03010403A (enExample)
MY (1) MY127495A (enExample)
NO (1) NO20035084L (enExample)
NZ (1) NZ529438A (enExample)
PE (1) PE20030042A1 (enExample)
PL (1) PL366786A1 (enExample)
RU (1) RU2298559C2 (enExample)
SK (1) SK14032003A3 (enExample)
TW (1) TWI295996B (enExample)
WO (1) WO2002092622A2 (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6777443B2 (en) * 2001-05-15 2004-08-17 Novartis Ag Dipeptide derivatives
WO2003004456A1 (en) * 2001-07-06 2003-01-16 Teva Pharmaceutical Industries Ltd. Process for the preparation of 7-amino syn 3,5-dihydroxy heptanoic acid derivatives via 6-cyano syn 3,5-dihydroxy hexanoic acid derivatives
WO2003027091A1 (en) * 2001-09-21 2003-04-03 Novartis Ag Pyrane derivatives as both ace- and nep- inhibitors
SI1467728T1 (sl) * 2002-01-17 2008-02-29 Novartis Ag Farmacevtski sestavki vkljucujoci valsartan in NEP inhibitorje
US7468390B2 (en) 2002-01-17 2008-12-23 Novartis Ag Methods of treatment and pharmaceutical composition
AU2003276960A1 (en) * 2002-06-13 2003-12-31 Novartis Ag Calcium salts of indole derived statins
EP1750862B1 (en) 2004-06-04 2011-01-05 Teva Pharmaceutical Industries Ltd. Pharmaceutical composition containing irbesartan
MX2007006279A (es) * 2004-12-15 2007-06-14 Solvay Pharm Gmbh Composiciones farmaceuticas que comprenden inhibidores de nep, inhibidores del sistema de produccion de endotelina endogena, e inhibidores de hmg coa-reductasa.
JP2008533109A (ja) * 2005-03-14 2008-08-21 オリオン コーポレーション 利尿を促進するための複合治療
US7390789B2 (en) * 2005-09-13 2008-06-24 William H Simmons Thio-containing inhibitors of aminopeptidase P, and compositions thereof
US7400236B2 (en) 2005-10-21 2008-07-15 Gm Global Technology Operations, Inc. Vehicular lane monitoring system utilizing front and rear cameras
AR057882A1 (es) 2005-11-09 2007-12-26 Novartis Ag Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra
US20120157387A1 (en) * 2006-11-28 2012-06-21 Apotex Technologies Inc. Orally bioavailable d-gamma-glutamyl-d-tryptophan
TW200838501A (en) * 2007-02-02 2008-10-01 Theravance Inc Dual-acting antihypertensive agents
TWI448284B (zh) * 2007-04-24 2014-08-11 Theravance Inc 雙效抗高血壓劑
TWI406850B (zh) 2007-06-05 2013-09-01 Theravance Inc 雙效苯并咪唑抗高血壓劑
WO2009035543A1 (en) 2007-09-07 2009-03-19 Theravance, Inc. Dual-acting antihypertensive agents
ES2385773T3 (es) 2007-12-11 2012-07-31 Theravance, Inc. Derivados de benzoimidazol, de doble acción, y su utilización como agentes antihipertensivos
US7989484B2 (en) 2008-04-29 2011-08-02 Theravance, Inc. Dual-acting antihypertensive agents
US7863309B2 (en) 2008-07-24 2011-01-04 Theravance, Inc. Dual-acting antihypertensive agents
JP5833000B2 (ja) 2009-07-07 2015-12-16 セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー 二重に作用するピラゾール抗高血圧症薬
ES2441419T3 (es) 2009-07-22 2014-02-04 Theravance, Inc. Agentes antihipertensivos de doble acción basados en oxazol
US8481549B2 (en) * 2010-01-19 2013-07-09 Theravance, Inc. Dual-acting thiophene, pyrrole, thiazole and furan antihypertensive agents
EA201391421A1 (ru) * 2011-03-31 2014-02-28 Апотекс Текнолоджиз Инк. Пролекарства d-гамма-глутамил-d-триптофана и d-гамма-глутамил-l-триптофана
US9212206B1 (en) 2014-11-24 2015-12-15 William H Simmons 4-Fluoro-Thio-containing inhibitors of APP2, compositions thereof and method of use
WO2018002673A1 (en) 2016-07-01 2018-01-04 N4 Pharma Uk Limited Novel formulations of angiotensin ii receptor antagonists
UY38072A (es) 2018-02-07 2019-10-01 Novartis Ag Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos
US11396497B2 (en) 2018-05-04 2022-07-26 New Mexico Tech University Research Park Corporation Proteasome inhibitors
CN113956183B (zh) * 2021-10-28 2023-06-20 成都市科隆化学品有限公司 一种Boc-Ser(Bzl)-OH及其制备方法
WO2024230583A1 (zh) * 2023-05-05 2024-11-14 上海济煜医药科技有限公司 一种短肽类化合物及其制备方法和医药应用

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3432307A1 (de) * 1984-09-03 1986-04-10 Boehringer Ingelheim KG, 6507 Ingelheim Aminosaeurederivate, verfahren zu ihrer herstellung und pharmazeutische zusammensetzungen
AU6733190A (en) 1989-11-27 1991-06-26 Santen Pharmaceutical Co. Ltd. Amino acid derivative
FR2679564A1 (fr) 1991-07-23 1993-01-29 Inst Nat Sante Rech Med Nouveaux acylmercaptoalcanoldipeptides, leur preparation et les compositions qui les contiennent.
ATE159515T1 (de) 1992-07-21 1997-11-15 Ciba Geigy Ag Oxamidsäure-derivate als hypocholesterämische mittel
US5432186A (en) * 1993-11-16 1995-07-11 Ciba-Geigy Corporation Cyclic amino acid derivatives
US5508266A (en) 1994-06-22 1996-04-16 Ciba-Geigy Corporation Gem-disubstituted amino acid derivatives
EP0820464A2 (en) 1995-03-31 1998-01-28 Takeda Chemical Industries, Ltd. Cysteine protease inhibitor
US6147114A (en) * 1995-04-25 2000-11-14 Fuji Yakuhin Kogyo Kabushiki Kaisha Highly water-soluble metalloproteinase inhibitors
DE69627483T2 (de) 1995-05-10 2004-04-01 Darwin Discovery Ltd., Slough Peptidartige stoffe, die metalloproteinasen und die tnf-freisetzung hemmen, und ihre therapeutische verwendung
WO1996040726A1 (en) * 1995-06-07 1996-12-19 Genta Incorporated Novel carbamate-based cationic lipids
US6245809B1 (en) * 1996-12-09 2001-06-12 Cor Therapeutics Inc. Integrin antagonists
US6492421B1 (en) * 1997-07-31 2002-12-10 Athena Neurosciences, Inc. Substituted phenylalanine type compounds which inhibit leukocyte adhesion mediated by VLA-4
DE19745151A1 (de) 1997-10-14 1999-04-15 Basf Ag Neue Verbindungen zur Behandlung von Krankheiten, die mit der biologischen Wirkung von Endothelin assoziiert sind
FR2770844A1 (fr) 1997-11-10 1999-05-14 Inst Nat Sante Rech Med Inhibiteurs de toxines clostridiales et compositions pharmaceutiques les contenant
CA2309792A1 (en) * 1997-11-12 1999-05-20 William C. Shakespeare Novel signal transduction inhibitors, compositions containing them
BR9909805A (pt) 1998-04-23 2000-12-26 Novartis Ag Certos inibidores de tiol de enzima de conversão de endotelina
WO1999055723A1 (en) 1998-04-23 1999-11-04 Novartis Ag Certain heteroaryl substituted thiol inhibitors of endothelin-converting enzyme
AU1719700A (en) 1998-12-31 2000-07-24 Aventis Pharmaceuticals Inc. Selective inhibitors of mmp-12
FR2788526B1 (fr) 1999-01-20 2002-07-05 Inst Nat Sante Rech Med Composes tripeptidiques utiles a titre d'hinhibiteurs selectifs de l'aminopeptidase a et compositions pharmaceutiques correspondantes
CO5160290A1 (es) 1999-03-29 2002-05-30 Novartis Ag Derivados de acido fenoxifeniloxamico sustituido .
US6503949B1 (en) * 1999-05-17 2003-01-07 Noro Nordisk A/S Glucagon antagonists/inverse agonists
GB9917909D0 (en) * 1999-07-31 1999-09-29 Synphar Lab Inc Cysteine protease inhibitors
DE60040397D1 (de) * 1999-08-27 2008-11-13 Cytovia Inc Substituierte alpha-hydroxy-säuren als caspase-hemmer und ihre verwendung
US6803383B2 (en) * 2000-03-27 2004-10-12 The Scripps Research Institute Inhibition of angiogenesis and tumor growth
AU2001287289A1 (en) 2000-04-03 2001-10-15 Bristol-Myers Squibb Company Vasopeptidase inhibitors to treat isolated systolic hypertensions
IL152081A0 (en) 2000-04-12 2003-05-29 Novartis Ag Novel medical use of aldosterone synthase inhibitors alone or in combination with at1-receptor antagonists
US20020013307A1 (en) 2000-05-23 2002-01-31 Pablo Lapuerta Use of vasopeptidase inhibitors to treat or slow the progression of cognitive dysfunction and to treat and/or prevent dementia
US6777443B2 (en) * 2001-05-15 2004-08-17 Novartis Ag Dipeptide derivatives

Also Published As

Publication number Publication date
PE20030042A1 (es) 2003-02-28
IL158772A0 (en) 2004-05-12
HUP0304084A3 (en) 2010-10-28
US6777443B2 (en) 2004-08-17
WO2002092622A3 (en) 2003-04-10
MXPA03010403A (es) 2004-03-09
HUP0304084A2 (hu) 2004-12-28
CZ20033077A3 (cs) 2004-02-18
PL366786A1 (en) 2005-02-07
BR0209652A (pt) 2004-07-13
US6992105B2 (en) 2006-01-31
WO2002092622A2 (en) 2002-11-21
SK14032003A3 (sk) 2004-06-08
TWI295996B (en) 2008-04-21
EP1392720A2 (en) 2004-03-03
NO20035084L (no) 2004-01-15
NZ529438A (en) 2005-07-29
JP2005504011A (ja) 2005-02-10
KR20030096401A (ko) 2003-12-24
US20040235754A1 (en) 2004-11-25
AU2002314067B2 (en) 2006-03-16
KR100908152B1 (ko) 2009-07-16
CN1649893A (zh) 2005-08-03
CA2449292A1 (en) 2002-11-21
US20060058242A1 (en) 2006-03-16
US20020183260A1 (en) 2002-12-05
RU2298559C2 (ru) 2007-05-10
WO2002092622A8 (en) 2004-01-22
MY127495A (en) 2006-12-29
JP4390458B2 (ja) 2009-12-24
CO5540347A2 (es) 2005-07-29
RU2003134153A (ru) 2005-06-10
EP2239268A1 (en) 2010-10-13
NO20035084D0 (no) 2003-11-14

Similar Documents

Publication Publication Date Title
AR035890A1 (es) Derivados de dipeptido con actividad inhibitoria de las enzimas convertidoras de angiotensina, de endotelina y de la enzima endopeptidasa neutra
BR0011130A (pt) Inibidores de metaloproteases
DK1039895T3 (da) Anvendelse af 3-benzoylphenyleddikesyrer, estere eller amider til behandling af GLC1A-glaukom
EA200000871A1 (ru) Ингибиторы фосфолипазных ферментов
EA200800924A1 (ru) Новые соединения, обладающие ингибирующей активностью в отношении натрийзависимого транспортера
NZ595196A (en) Peptide-based compounds for enzyme inhibition
ATE433973T1 (de) Azolylaminoazine als inhibitoren von proteinkinasen
IS6069A (is) N-cýanómetýlamíð sem próteasalatar
BR0316585A (pt) Derivados de ácido glioxìlico aril, ariloxi e alquiloxi 1h-indol-3-il substituìdos como inibidores do inibidor-1 do ativador do plasminogênio (pai-1)
DK0966465T3 (da) Inhibitorer af IMPDH-enzymer
NO20074647L (no) 3,4 dihydro-1H-isoquinolin-2-karboksylsyre-5-ammopyridin-2-yl estere
BR0109353A (pt) Cadeia lateral heterocìclica contendo inibidores de metaloprotease
BR0007778A (pt) Peptidila cetonas heterocìclicas úteis como inibidores de triptase
AR044650A1 (es) Derivados de tiofeno - pirimidinona y su uso en la terapia de enfermedades que requieren la inhibicion de la enzima 17b-hidroxiesteroide-dehidrogenasa.
MA56661B1 (fr) Formes cristallines de 7-chloro-2-(4-(3-méthoxyazétidine-1-yl))cyclohexyl) 2,4-diméthyl-n-((6-méthyl-4-(méthylthio)-2-oxo-1,2-dihydropyridine-3-yl) méthyl)benzo[d][1,3]dioxole-5-carboxamide
DE60319083D1 (de) Pharmazeutische verbindung und methoden zur behandlung von menschlichen karzinomen mittels arginin entzug
BRPI0517621A (pt) sais hidroxibenzoato de compostos de metanicotina
DK0811001T3 (da) Benzothiazindioxider som endothelinantagonister
BR0315662A (pt) Derivados de 1-(4-benzil-piperazin-1-il)-3-fenil-propenona
ES2421447T3 (es) Métodos para proteger frente a apoptosis usando lipopéptidos
NO20045126L (no) N-acyl piperidinderivater for anvendelse som melanokortinreseptorligander i behandling av fodeforstyrrelser
UY25888A1 (es) Derivados del ácido 4-biarilbutirico y 5-biarilpentanoico sustituidos útiles como inhibidores de la metalproteasa de matriz para el tratamiento de enfermedades respiratorias
BR0009674A (pt) Composto, droga, e, uso de composto
DE60031686D1 (de) Pyrazinone, diese verbindungen enthaltende zusammenstellungen
ATE302587T1 (de) Gebissreinigungsmittel

Legal Events

Date Code Title Description
FB Suspension of granting procedure